Intraperitoneal Chemotherapy Using Fluorouracil Implants Combined With Radical Resection and Postoperative Adjuvant Chemotherapy for Stage III Gastric Cancer: A Multi-Center, Randomized, Open-Label, Controlled Clinical Study

Yan Xu, Rupeng Zhang, Chunfeng Li, Zhe Sun, Jingyu Deng, Xiaona Wang, Xuewei Ding, Baogui Wang, Qiang Xue, Bin Ke, Hongjie Zhan, Ning Liu, Yong Liu, Xuejun Wang, Han Liang, Yingwei Xue, Huimian Xu, Yan Xu, Rupeng Zhang, Chunfeng Li, Zhe Sun, Jingyu Deng, Xiaona Wang, Xuewei Ding, Baogui Wang, Qiang Xue, Bin Ke, Hongjie Zhan, Ning Liu, Yong Liu, Xuejun Wang, Han Liang, Yingwei Xue, Huimian Xu

Abstract

Background: Reducing peritoneal recurrence after radical surgery is an important choice to improve the prognosis of patients with advanced gastric cancer. Intraoperative intraperitoneal chemotherapy has the potential to be a promising treatment strategy. In the present study, we conducted a multi-center, randomized, controlled clinical study to evaluate the efficacy and safety of intraoperative intraperitoneal chemotherapy using sustained-release fluorouracil implants plus radical gastrectomy and adjuvant chemotherapy for cTNM stage III gastric cancer.

Methods: The patients were randomized into intraperitoneal chemotherapy group (sustained-release fluorouracil implants administration after standard D2 radical gastrectomy, and followed by XELOX adjuvant chemotherapy) and control group (standard D2 radical gastrectomy, and followed by XELOX adjuvant chemotherapy). A total of 122 patients from three centers were enrolled from September 2015 to February 2017.

Results: One hundred and two eligible patients completed the treatment course. The median follow-up time was 41.7 months (36.1-52.9 months). The 3-year progression-free survival rate and overall survival of patients in the intraperitoneal chemotherapy group were 43.9% and 49.1%, respectively, which were significantly better than those of the control group, 31.0% and 38.4%. In the intraperitoneal chemotherapy group, the number of cases with peritoneal recurrence was significantly less than that of the control group, 9 cases (17.3%) vs. 19 cases (44.2%). There were neither significant differences between the groups in the incidence of hematogenous metastasis, lymph node metastasis, nor local metastasis.

Conclusion: For cTNM stage III gastric cancer, intraoperative sustained-release fluorouracil implants after radical resection combined with postoperative adjuvant chemotherapy, could significantly reduce the risk of peritoneal recurrence and prolong PFS.Clinical Trial Registration: https://ichgcp.net/clinical-trials-registry/NCT02269904" title="See in ClinicalTrials.gov">NCT02269904).

Keywords: fluorouracil implants; gastric cancer; intraperitoneal chemotherapy; metastasis; survival.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Xu, Zhang, Li, Sun, Deng, Wang, Ding, Wang, Xue, Ke, Zhan, Liu, Liu, Wang, Liang, Xue and Xu.

Figures

Figure 1
Figure 1
Flowchart of the participants.
Figure 2
Figure 2
Kaplan-Meier curve of overall survival.
Figure 3
Figure 3
Kaplan-Meier curve of progression-free survival.

References

    1. Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic Significance of Peritoneal Washing Cytology in Patients With Gastric Cancer. Br J Surg (2012) 99(3):397–403. 10.1002/bjs.7812
    1. Lee JH, Son SY, Lee CM, Ahn SH, Park DJ, Kim HH. Factors Predicting Peritoneal Recurrence in Advanced Gastric Cancer: Implication for Adjuvant Intraperitoneal Chemotherapy. Gastric Cancer (2014) 17(3):529–36. 10.1007/s10120-013-0306-2
    1. Han TS, Kong SH, Lee HJ, Ahn HS, Hur K, Yu J, et al. . Dissemination of Free Cancer Cells From the Gastric Lumen and From Perigastric Lymphovascular Pedicles During Radical Gastric Cancer Surgery. Ann Surg Oncol (2011) 18(10):2818–25. 10.1245/s10434-011-1620-8
    1. Li XF, Carlin S, Urano M, Russell J, Ling CC, O’Donoghue JA. Visualization of Hypoxia in Microscopic Tumors by Immunofluorescent Microscopy. Cancer Res (2007) 67(16):7646–53. 10.1158/0008-5472.CAN-06-4353
    1. Huang JY, Xu YY, Sun Z, Zhu Z, Song YX, Guo PT, et al. . Comparison Different Methods of Intraoperative and Intraperitoneal Chemotherapy for Patients With Gastric Cancer: A Meta-Analysis. Asian Pac J Cancer Prev (2012) 13(9):4379–85. 10.7314/apjcp.2012.13.9.4379
    1. Sun J, Song Y, Wang Z, Gao P, Chen X, Xu Y, et al. . Benefits of Hyperthermic Intraperitoneal Chemotherapy for Patients With Serosal Invasion in Gastric Cancer: A Meta-Analysis of the Randomized Controlled Trials. BMC Cancer (2012) 12:526. 10.1186/1471-2407-12-526
    1. Zhu L, Xu Z, Wu Y, Liu P, Qian J, Yu S, et al. . Prophylactic Chemotherapeutic Hyperthermic Intraperitoneal Perfusion Reduces Peritoneal Metastasis in Gastric Cancer: A Retrospective Clinical Study. BMC Cancer (2020) 20(1):827. 10.1186/s12885-020-07339-6
    1. Xie TY, Wu D, Li S, Qiu ZY, Song QY, Guan D, et al. . Role of Prophylactic Hyperthermic Intraperitoneal Chemotherapy in Patients With Locally Advanced Gastric Cancer. World J Gastrointest Oncol (2020) 12(7):782–90. 10.4251/wjgo.v12.i7.782
    1. Yonemura Y, de Aretxabala X, Fujimura T, Fushida S, Katayama K, Bandou E, et al. . Intraoperative Chemohyperthermic Peritoneal Perfusion as an Adjuvant to Gastric Cancer: Final Results of a Randomized Controlled Study. Hepatogastroenterol (2001) 48(42):1776–82.
    1. Yamashita K, Tsunoda S, Gunji S, Murakami T, Suzuki T, Tabata Y, et al. . Intraperitoneal Chemotherapy for Peritoneal Metastases Using Sustained Release Formula of Cisplatin-Incorporated Gelatin Hydrogel Granules. Surg Today (2019) 49(9):785–94. 10.1007/s00595-019-01792-y
    1. Kwon OK, Chung HY, Yu W. Early Postoperative Intraperitoneal Chemotherapy for Macroscopically Serosa-Invading Gastric Cancer Patients. Cancer Res Treat (2014) 46(3):270–9. 10.4143/crt.2014.46.3.270
    1. Yuan H, Zheng B, Tu S. Clinical Research of Intraperitoneal Implantation of Sustained-Release 5-Fluorouracil in Advanced Colorectal Cancer. World J Surg Oncol (2015) 13:320. 10.1186/s12957-015-0737-9
    1. Yang XJ, Huang CQ, Suo T, Mei LJ, Yang GL, Cheng FL, et al. . Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy Improves Survival of Patients With Peritoneal Carcinomatosis From Gastric Cancer: Final Results of a Phase III Randomized Clinical Trial. Ann Surg Oncol (2011) 18(6):1575–81. 10.1245/s10434-011-1631-5
    1. Yonemura Y, Prabhu A, Sako S, Ishibashi H, Mizumoto A, Takao N, et al. . Long Term Survival After Cytoreductive Surgery Combined With Perioperative Chemotherapy in Gastric Cancer Patients With Peritoneal Metastasis. Cancers (Basel) (2020) 12(1):116. 10.3390/cancers12010116
    1. Cui HB, Ge HE, Bai XY, Zhang W, Zhang YY, Wang J, et al. . Effect of Neoadjuvant Chemotherapy Combined With Hyperthermic Intraperitoneal Perfusion Chemotherapy on Advanced Gastric Cancer. Exp Ther Med (2014) 7(5):1083–8. 10.3892/etm.2014.1599
    1. Fujimoto S, Takahashi M, Mutou T, Kobayashi K, Toyosawa T. Successful Intraperitoneal Hyperthermic Chemoperfusion for the Prevention of Postoperative Peritoneal Recurrence in Patients With Advanced Gastric Carcinoma. Cancer (1999) 85(3):529–34. 10.1002/(SICI)1097-0142(19990201)85:3<529::AID-CNCR3>;2-9
    1. Hamazoe R, Maeta M, Kaibara N. Intraperitoneal Thermochemotherapy for Prevention of Peritoneal Recurrence of Gastric Cancer. Final Results of a Randomized Controlled Study. Cancer (1994) 73(8):2048–52. 10.1002/1097-0142(19940415)73:8<2048::AID-CNCR2820730806>;2-Q
    1. Handali S, Moghimipour E, Rezaei M, Ramezani Z, Dorkoosh FA. PHBV/PLGA Nanoparticles for Enhanced Delivery of 5-Fluorouracil as Promising Treatment of Colon Cancer. Pharm Dev Technol (2020) 25(2):206–18. 10.1080/10837450.2019.1684945
    1. Fernandes E, Ferreira D, Peixoto A, Freitas R, Relvas-Santos M, Palmeira C, et al. . Glycoengineered Nanoparticles Enhance the Delivery of 5-Fluoroucil and Paclitaxel to Gastric Cancer Cells of High Metastatic Potential. Int J Pharm (2019) 570:118646. 10.1016/j.ijpharm.2019.118646
    1. de Bree E, Michelakis D. An Overview and Update of Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. Expert Opin Pharmacother (2020) 21(12):1479–92. 10.1080/14656566.2020.1766024
    1. Chen J, Zhang J, Wang C, Yao K, Hua L, Zhang L, et al. . Safety of Implanting Sustained-Release 5-Fluorouracil Into Hepatic Cross-Section and Omentum Majus After Primary Liver Cancer Resection. Int J Immunopathol Pharmacol (2016) 29(3):475–9. 10.1177/0394632016648176
    1. Li L, Li C, Zhou J. Effective Sustained Release of 5-FU-Loaded PLGA Implant for Improving Therapeutic Index of 5-FU in Colon Tumor. Int J Pharm (2018) 550(1-2):380–7. 10.1016/j.ijpharm.2018.07.045
    1. Longley DB L, Harkin DP, Johnston PG. 5-Fluorouracil: Mechanisms of Action and Clinical Strategies. Nat Rev Cancer (2003) 3(5):330–8. 10.1038/nrc1074
    1. Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V. 5-Fluorouracil and Other Fluoropyrimidines in Colorectal Cancer: Past, Present and Future. Pharmacol Ther (2020) 206:107447. 10.1016/j.pharmthera.2019.107447
    1. Goirand F, Lemaitre F, Launay M, Tron C, Chatelut E, Boyer JC, et al. . How can We Best Monitor 5-FU Administration to Maximize Benefit to Risk Ratio? Expert Opin Drug Metab Toxicol (2018) 14(12):1303–13. 10.1080/17425255.2018.1550484
    1. Wilson PM, Danenberg PV, Johnston PG, Lenz HJ, Ladner RD. Standing the Test of Time: Targeting Thymidylate Biosynthesis in Cancer Therapy. Nat Rev Clin Oncol (2014) 11(5):282–98. 10.1038/nrclinonc.2014.51
    1. Li JQ, Yang JC, Liang JX, Wang SL. Pharmacokinetic Study and Clinical Evaluation of a Slow-Release 5-Fluorouracil Implant in Pancreatic Cancer Patients. Anticancer Drugs (2016) 27(1):60–5. 10.1097/CAD.0000000000000293

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다